Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FDA

The FDA and Juul are fighting over a vape ban, but the role of e-cigarettes in the world of tobacco abuse is not clear-cut

On June 23, 2022, the U.S. Food and Drug Administration announced that all Juul products must be removed from U.S. markets. This decision essentially broadened an existing ban on teen use of the company’s nicotine e-cigarettes to include adults as well. The next day, Juul asked a federal appeals court…

The Conversation

Beyond Air Scores First FDA Approval For LungFit PH In Respiratory Failure

The FDA has approved Beyond Air Inc's (NASDAQ:XAIR) LungFit PH to treat term and near-term neonates with hypoxic respiratory failure (often referred to as persistent pulmonary hypertension of the newborn or PPHN). LungFit PH is the initial device from the LungFit therapeutic platform of nitric oxide generators. It is the first FDA-approved product…

Benzinga

LiveOne And 24 Stocks Moving Premarket

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 92.9% to $0.2295 in pre-market trading. Allena Pharmaceuticals said it previously entered into at market issuance sales agreement with B. Riley Securities.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Oyster Point Outlines Restructuring Plan With Savings Of Up To $48M In 2023

Oyster Point Pharma Inc (NASDAQ:OYST) will implement an operating expense streamlining plan to reduce employee and non-employee expenses (up to 50 roles) across the organization. The company plans to continue to drive the launch of Tyrvaya with approximately 150-200 field-based sales resources. The plan is expected to reduce operating expenses by approximately $6…

Benzinga

COVID vaccine strategy still murky after FDA experts meet

Axios

InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday

Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.

Benzinga

FDA approves use of Evusheld

The Food and Drug Administration has approved the use of Evusheld, a combination of long-acting antibodies, for prevention of Covid-19, FDA director Paisal Dankhum said on Wednesday.

Bangkok Post

Read news from The Economist, FT, and more,
with one subscription

COVID shots should get omicron-targeted update, FDA advisers say

COVID-19 shots from Pfizer Inc. and Moderna Inc. should be updated to include components that target the highly transmissible omicron variant, the version of the virus that causes most of the world’s cases, U.S. regulatory advisers said.

Tribune News Service

US medical experts call for Omicron-specific Covid boosters

Washington (AFP) - A panel of US medical experts on Tuesday called for Omicron-specific boosters this fall, as anticipation mounts that Covid vaccines will be needed on an ongoing seasonal basis, as is the case for influenza.

AFP

Canada needs to invest more money into science innovation to help prevent the next global crisis

Canada has lagged behind its peer nations in innovation for decades. Currently, Canada is ranked 11th out of the 16 similarly developed countries assessed. While our “C” grade is a moderate improvement over our previous “D” grade, innovation still remains a barrier to high-quality job creation and economic prosperity in…

The Conversation

Verrica Holds Type A Meeting With FDA For Potential Approval Of Skin Infection Candidate

The U.S. Food and Drug Administration (FDA) convened a Type A meeting with Verrica Pharmaceuticals (NASDAQ: VRCA) regarding the course of action for the clearance of its drug candidate VP-102.

Benzinga

Schrödinger's Initial-Stage Cancer Study Gains FDA Clearance

Schrödinger Inc. (NASDAQ: SDGR) announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for the drug candidate SGR-1505 in patients with relapsed or refractory B-cell lymphoma.

Benzinga

The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder

Psychedelic biopharma company Cybin Inc. (NEO: CYBN) has received FDA Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating major depressive disorder (MDD).

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

New weight-loss treatment is marked by heavy marketing and modest results

First came the “edible billboard,” which appeared last year during the holidays in New York’s East Village loaded with cake treats. Then, in late January, came the national marketing campaign, with TV and digital media promoting the idea that trying to lose weight doesn’t mean a person can’t enjoy eating.

Benzinga

BCTX: New Sites Expand Bria-IMT Trial

By John Vandermosten, CFA NASDAQ:BCTX READ THE FULL BCTX RESEARCH REPORT

Benzinga

ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer

ESSA Pharma Inc (NASDAQ:EPIX) presented clinical results from the Phase 1a dose-escalation study of EPI-7386 as a monotherapy for metastatic castration-resistant prostate cancer (mCRPC) resistant to current standard-of-care therapies. The initial data from 36 patients demonstrate that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily…

Benzinga

Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues

Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Spero Therapeutics' Shares Plunge As FDA Issued Refusal Letter For Urinary Tract Infection Candidate

The U.S.

Axios

Abortion rights activists plot next legal steps

Abortion rights advocates are considering a number of options to legally challenge state bans.

Salon

Throw out this Panera corn chowder ASAP

The product in question was only distributed in select supermarkets across 12 different states

Benzinga

New York Judge Denies Bristol Myers Claim To Dismiss Lawsuit Over Delayed Cancer Drug Approval: Reuters

According to a Reuters report, U.S. District Judge Jesse Furman in Manhattan refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co (NYSE:BMY) of delaying its Breyanzi cancer drug to avoid payments to former Celgene shareholders. The judge rejected Bristol Myers' claim that it was never properly notified about its alleged default…

Benzinga

3 Women's Health Stocks Are Soaring Following Roe v. Wade Ruling

Three days after the U.S. Supreme Court struck down Roe v. Wade in one of the most potentially impactful rulings of the last century, a handful of women's health stocks are on the move on Monday in response to the news.

Investors Business Daily

Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why

The Food and Drug Administration could be nearing a decision on Axsome Therapeutics' depression treatment, and AXSM stock rocketed Monday.

The Independent UK

Medication abortion is common, effective, and under attack by Republicans

Most abortions in the US and overseas involve pills that can be taken at home, but GOP lawmakers have launched a new war on drugs, Alex Woodward reports

1 … 138 139 140 141

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.